PROBLEM TO BE SOLVED: To provide a powder formulation which reduces an adverse reaction risk of pirfenidone expressing the adverse reaction of drug-induced photodermatosis, and increases a therapeutic effect.SOLUTION: There are provided a solid dispersing element containing pirfenidone and a sustained-release base material, and a powder formulation containing the solid dispersing element and a carrier. The formulation can reduce a dosage amount by enhancing medicinal value in local lung by readily converting to aerosol to enable an inhalation therapy. A lung specific delivery technique can inhibit skin transition of the drug and can inhibit photodermatosis which is an adverse reaction.
